CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.42 | 0.02 | -0.08 |
| FCF Yield | -4.36% | -5.49% | -16.86% | 7.95% |
| EV / EBITDA | -7.26 | -23.72 | -4.92 | 12.92 |
| Quality | ||||
| ROIC | -21.70% | -10.48% | -31.24% | 13.99% |
| Gross Margin | -215.00% | 64.91% | -25,186.70% | 98.03% |
| Cash Conversion Ratio | 0.39 | 1.70 | 0.76 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 331.38% | -26.00% | -15.36% | 46.64% |
| Free Cash Flow Growth | 46.88% | 48.90% | -216.55% | 278.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.74 | -0.05 | -1.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -9.84 | 0.00 |
| Cash Conversion Cycle | 212.02 | 89.76 | -127.88 | -301.10 |